TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Risk Factors for Low Back Pain in Adults A 23-year Prospective Cohort Study of 14-15-year-old Schoolchildren.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Being a member of the original Western Zealand cohort~* Ability to understand and write in Danish~* Having access to the Danish digital mail system e-Boks. (Access to e-Boks is mandatory in Denmark unless you have special needs)~Exclusion Criteria:~We have no formal exclusion criterias

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Inception cohort, former pupils in different schools in Western Zealand (Type: None): 1327 former Western Zealand pupils (originally 1389). Aged 14-15 in 1997. This is the first follow up on this cohort.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: PROphylaxis in NOn Major Orthopaedic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed and dated informed consent form,~2. Age ≥ 18 years,~3. Hospitalised for non-major orthopaedic surgery and requiring thromboprophylaxis according to the investigator's judgement on VTE risk such Achilles' repair, hip (except femoral neck and trochanteric fracture), knee, tibial plateau, femur (non femoral head), tibial and ankle fractures and tibial osteotomy, tibial transposition, arthrodesis of leg articulation, ligament repair of the knee or the ankle or any elective orthopaedic limb surgery requiring thromboprophylaxis).~Exclusion Criteria:~1. Major orthopaedic surgery Hip and Knee replacement, femoral neck and trochanteric fractures, spine surgery,~2. Low risk surgery without patient VTE risk: foot surgery (Hallux Valgus), material removal,~3. Delay between hospitalisation and randomisation greater than two days,~4. Women of childbearing potential not using a reliable contraceptive method throughout the study period (a list of reliable contraceptive methods is provided in the accompanying SPM),~5. Women pregnant or breast-feeding during the study period,~6. Body weight less than 50 kg (to avoid bleeding over risk) or over 120 kg,~7. Long term treatment with VKA therapy or NOAC,~8. Concomitant treatment with clopidogrel, prasugrel and ticagrelor,~9. Platelet count \< 100 Giga/L,~10. Documented history of acquired or inherited bleeding disorder (e.g., von Willebrand's disease),~11. Severe renal failure with calculated creatinine clearance (Cockcroft Formula) \< 30 mL/min,~12. Severe hepatic insufficiency with prothrombin time \< 60% or liver impairment associated with coagulation disorders,~13. History of thrombocytopenia,~14. Any other current significant medical condition that might interfere with treatment evaluation according to the investigator's judgement,~15. Known hypersensitivity or other severe reaction to any component of the investigational medicinal product(s),~16. Participation in another clinical study involving an investigational medicinal product within 30 days prior to inclusion or concomitantly with this study,~17. Active bleeding or contraindication to anticoagulant therapy~18. Chronic alcoholic intoxication,~19. Anticipated poor compliance of subject with study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: Rivaroxaban treatment (Type: EXPERIMENTAL): Rivaroxaban active substance plus a placebo of enoxaparin
- Grouyp 2: Enoxaparine treatment (Type: ACTIVE_COMPARATOR): Enoxaparin active substance plus a placebo tablet of Rivaroxaban

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of the Astym Technique, the Graston Technique, and Therapeutic Ultrasound in the Treatment of Lateral Epicondylosis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clients who are admitted to NYULMC Center for Musculoskeletal Care for outpatient occupational or physical therapy with a diagnosis of lateral epicondylosis will be included. To participate in the study participants must:~* Be able to follow a home exercise program~* Be able to consent to participation in the research study~Exclusion Criteria:~* Clients who are deemed unable to consent to participation in the research study and/or unable to following a home exercise program will not be included in this study~* Clients with additional acute orthopedic injuries and/or surgeries to the involved upper extremity will not be included in this study.~* Clients with open wounds of the involved upper extremity that will interfere with treatment techniques will not be involved in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Therapeutic ultra sound (Type: ACTIVE_COMPARATOR): None
- Astym Treatment Technique (Type: ACTIVE_COMPARATOR): None
- Graston Treatment Technique (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dose-ranging Study to Evaluate Efficacy of SLV339 in Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subject \> 18 years;~* Pancreatic exocrine insufficiency confirmed and documented in medical history by either a pathophysiological direct or indirect pancreatic function test or clinical symptoms of steatorrhea stool fat that resolved or improved substantially upon pancreatic enzyme supplementation;~* Patients on a stable daily dose of pancreatic enzymes for 3 months;~* Subjects with CP with or without partial pancreatectomy due to CP, confirmed in medical history by either CT , ERCP, plain film with pancreatic calcifications, ultra-sonography (calcifications, duct dilatation), magnetic resonance pancreatography, endoscope ultrasound, other radiological diagnosis captured by tools such as Cambridge classification and /or histology;~* CFA \< 80% at time of randomization~Exclusion Criteria:~* Evidence of major surgery (except gall bladder removal or appendectomy) or other relevant diseases as revealed by history, physical examination, and laboratory assessments which may interfere with the absorption, distribution, metabolism or elimination of the study drug or constitute a risk factor when taking the study medication;~* Investigational drug intake within 90 days prior to the pre-assessment visit;~* Ileus or acute abdomen;~* Allergic disease such as hypersensitivity pneumonitis, aspergillus mediated asthma or allergic broncho-pulmonary aspergillosis;~* Stenosis or regurgitation of the esophagus or stomach;~* Known HIV infection, acute phase of CP

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient understands study requirements and has given his/her written informed consent on an Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approved consent form.~* Parkinson's disease diagnosis consistent with UK Parkinson's Disease Society Brain Bank Diagnostic criteria~* Minimum of 3 years since diagnosis.~* Meet Hoehn and Yahr PD stage~* Good response to levodopa~* Stable regimen of anti-PD medications~* Patients must have been taking a levodopa-containing anti-PD medication continuously for at least the previous 12 months~* Patient has documented a minimum amount of Off time.~* If of childbearing potential (male and female) must use an acceptable method of contraception~Exclusion Criteria:~* Previous tozadenant study participation~* Current or recent participation in another study.~* Secondary or atypical parkinsonism~* Neurosurgical intervention for PD (except DBS if electrode placement has been performed over 12 months prior to screening)~* Patient is taking apomorphine, budipine, istradefylline, tolcapone, or DUOPA™/Duodopa®~* Treatment with excluded medications~* Untreated or uncontrolled hyperthyroidism or hypothyroidism~* Clinically significant out-of-range laboratory~* MMSE out of range~* Current episode of major depression (stable treatment for depression is permitted).~* Recent suicide attempt or suicidal ideation type 4 or type 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS)~* Women lactating or pregnant~* Hypersensitivity to any components of tozadenant or excipients~* Abnormal findings on the physical or neurological examination, or medical history that would make the patient unsuitable for the study~* History of hepatitis or cholangitis

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tozadenant (Type: EXPERIMENTAL): 120 mg twice daily. At Week 2 or thereafter doses of 60 mg BID and 120 mg BID will be permitted.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine Patient-Controlled Analgesia for Acute Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to 18 years~* Total Injury Severity Score greater than 9~* Functioning intravenous catheter present per standard of care~* Patient planned to receive PCA for acute pain per standard of care~* Patient ability to effectively use a PCA device as assessed by the primary attending trauma service~* Negative pregnancy test for women of childbearing age~Exclusion Criteria:~* Body mass index greater than 35~* History of active psychiatric disease~* Acute or chronic liver or renal failure~* History of heart failure or coronary artery disease~* Patients with documented chronic pain syndrome who use opioids as maintenance medication in outpatient therapy~* Patients who abuse alcohol and are at high risk for alcohol withdrawal~* Intubated patients~* Glasgow Coma Scale score less than 13, or motor subscore less than 6~* Documented allergy to ketamine, hydromorphone, or lorazepam~* Pregnancy~* Incarceration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Ketamine 90mg/30 mL PCA (3 mg/mL)
- Hydromorphone (Type: ACTIVE_COMPARATOR): Hydromorphone 6mg/30 mL PCA (0.2 mg/mL)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Acute Versus Subacute Angioplasty in Patients With NON-ST-Elevation Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Angina~* Elevated biomarkers (Point-of-care testing) either prehospital or immediately on admission~* ST-segment depression of 0.2mV or more in two contiguous leads or 0.1 mV or more in four contiguous leads.~* Patient can be randomized either in the prehospital phase or within 30 minutes of admission to a hospital~Exclusion Criteria:~* Tachycardia \> 120~* Age \< 18 or \> 80 years~* Indication for PPCI already fulfilled~* Dementia~* Patient cannot understand the study information~* Presumed troponisme~* Left ventricular hypertrophy~* Known dialysis~* Previous CABG~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group I: PPCI (Type: EXPERIMENTAL): Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI
- Conventional: Group II (Type: NO_INTERVENTION): Patients are treated as today: Admission to local hospital, Low-molecular-weight heparin (LMWH), Aspirin, ADP-blocker and within 72 hours transfer for angiography/angioplasty. Patients with a Grace score \> 140 will be transferred for angiography/angioplasty within 24 hours. Patients with refractory angina, severe heart failure, life-threatening ventricular arrhythmias or haemodynamic instability will be transferred acutely for angiography/angioplasty according to the european guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of non-small cell lung cancer (NSCLC) meeting 1 of the following criteria:~  * Medically inoperable or unresectable stage II, IIIA, or IIIB disease~ * Post-resection intrathoracic tumor recurrence~* Measurable disease by computed tomography(CT) scan~* No evidence of small cell histology~* No significant pleural effusion on chest x-ray or malignant pleural effusion on cytology~* No metastatic disease~* Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status 0-1~* Absolute granulocyte count ≥ 2,000/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 8.0 g/dL~* Bilirubin ≤ 1.5 mg/dL~* Serum glutamic oxaloacetic transaminase (SGOT) ≤ 1.5 times upper limit of normal (unless abnormality is caused by documented benign disease)~* Creatinine ≤ 1.5 mg/dL~* Weight loss ≤ 10% within the past 3 months~* Forced expiratory volume (FEV) 1 ≥ 1,000 cc~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after completion of study treatment~Exclusion Criteria:~* Synchronous (except for nonmelanomatous skin cancer) or prior invasive malignancy, unless disease free for \> 3 years~* Myocardial infarction within the past 6 months~* Symptomatic heart disease, including any of the following:~  * Angina~ * Congestive heart failure~ * Uncontrolled arrhythmia~* Active infection or fever ≥ 38.5°C within the past 3 days~* Known hypersensitivity to any of the components of oxaliplatin or docetaxel~* Prior thoracic or neck radiotherapy~* Prior docetaxel or oxaliplatin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemoradiation Treated Patients (Type: EXPERIMENTAL): Patients receiving Docetaxel, Oxaliplatin and radiotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Androgen Deprivation Therapy Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men 18 years of age or older with prostate cancer~* Planning to undergo long-term (at least 12 months) ADT~* No known history of diabetes~* No history of ADT~Exclusion Criteria:~* History of ADT or any prior diagnosis of hypogonadism~* Fasting glucose or oral glucose tolerance test results in the diabetic range~* Heart failure (NY classification III or IV)~* Testosterone level less than 250 ng/dl on screening~* History of heart attack or open-heart surgery within the past 6 months~* Use of steroids within the past 3 months, including prednisone, cortisone injections, inhaled steroids (topical steroids are acceptable)~* Use of anabolic steroids (testosterone, DHEA, DHEAS) or any growth promoters (growth hormone itself or analogs of growth hormone) in the past 12 months~* Liver function tests more than 3 times upper normal limits~* Undergoing intermittent ADT~* Uncontrolled thyroid disease (hyper- or hypo-thyroidism)~* Anemia, defined as hematocrit less than 38%~* Not physically capable of completing the tests

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Participants receiving ADT and pioglitazone
- 2 (Type: None): Participants receiving ADT only
- 3 (Type: None): Participants not receiving ADT and in remission from prostate cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:-Adult participants with Atopic Dermatitis (skin rash, inflammation) involving greater than or equal to 10 percent body surface area~* Female participants must have a negative serum pregnancy test at screening~* With the exception of well-controlled asthma, allergic rhinitis and food allergies, participants must be in good general health prior to study participation with no clinically significant abnormalities as assessed by the investigator and determined by medical history, physical examination, blood chemistry, complete blood count, coagulation tests, urinalysis and electrocardiogram (ECG)~* Male subjects must consent to utilize a medically acceptable method of contraception throughout the study including the washout period and for three months after the study is completed~* Female participants of child bearing potential must consent to utilize a medically acceptable method of contraception throughout the study including the washout period and for three months after the study is completed Exclusion Criteria:-Evidence of clinically significant hepatic, reproductive, gastrointestinal, renal, hematologic, pulmonary, neurologic, respiratory (with the exception of well-controlled asthma), endocrine or cardiovascular abnormalities or psychiatric disorders~* Participants with screening alanine aminotransferase, alkaline phosphatase or direct bilirubin levels above the upper limit of normal~* Evidence of any skin condition that in the opinion of the investigator would interfere with assessment of atopic dermatitis~* Use of any investigational drugs within the previous 30 days prior to dosing or within a period of less than five times the drug's half-life, whichever is longer~* Use of any biologic within a period of 5 times its half-life

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- JNJ-26113100 (50 mg) once daily (Type: EXPERIMENTAL): None
- JNJ-26113100 (100 mg) once daily (Type: EXPERIMENTAL): None
- JNJ-26113100 (100 mg) twice daily (Type: EXPERIMENTAL): None
- JNJ-26113100 (250 mg) twice daily (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Providing Patients Realistic Expectations of Postoperative Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Undergoing open colorectal surgery Able to understand and sign and informed consent form~Exclusion Criteria:~* Age \< 18 years~* Unable to complete post-operative CMS questionnaire~* Inability to understand the English language Absolute contraindication to epidural placement (patient refusal, requiring resumption of therapeutic anticoagulation after surgery, anaphylaxis to local anesthetics, local or systemic infections, bleeding diathesis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Standard preoperative assessment
- Education (Type: ACTIVE_COMPARATOR): Pre-operative education regarding post-operative pain expectations

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy